MAV
NVS icon

Mason & Associates (Virginia)’s Novartis NVS Stock Holding History

Mason & Associates (Virginia)’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,954
Closed -$1.93M – 68
2024
Q1 		$1.93M Buy
+19,954
New +$2.05M 1.47% 32

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Cullen Capital Management New York $9.75B AUM 21.81% 1-Year Est. Return

Mason & Associates (Virginia)'s NVS Position: Q2 2024 in Review

Mason & Associates (Virginia) sold out of Novartis (NVS) in Q2 2024, closing a stake of 19,954 shares — an estimated $1.93M sold.

Mason & Associates (Virginia) first reported a position in NVS in Q1 2024 and held it in 1 quarter. The position peaked at $1.93M in Q1 2024. 1,306 funds tracked by Wall St. Rank hold NVS as of Q2 2024.

  • Mason & Associates (Virginia) reported no remaining Novartis position as of Q2 2024 after selling out during the quarter.
  • Mason & Associates (Virginia) sold 19,954 Novartis shares in Q2 2024, an estimated $1.93M.
  • Mason & Associates (Virginia) first reported a position in Novartis in Q1 2024 and held it in 1 quarter.
  • Mason & Associates (Virginia)'s Novartis position peaked at $1.93M in Q1 2024.
  • 1,306 funds tracked by Wall St. Rank held Novartis as of Q2 2024.

Based on Mason & Associates (Virginia)'s 13F filing for Q2 2024, filed 16 Jul 2024.